Cargando…

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19

BACKGROUND: The most severe cases of Coronavirus-Disease-2019 (COVID-19) develop into Acute Respiratory Distress Syndrome (ARDS). It has been proposed that oxygenation may be inhibited by extracellular deoxyribonucleic acid (DNA) in the form of neutrophil extracellular traps (NETs). Dornase alfa (Pu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holliday, Zachary M., Earhart, Alexander P., Alnijoumi, Mohammed M., Krvavac, Armin, Allen, Lee-Ann H., Schrum, Adam G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564175/ https://www.ncbi.nlm.nih.gov/pubmed/34745093 http://dx.doi.org/10.3389/fimmu.2021.714833

Ejemplares similares

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
por: Earhart, A.P., et al.
Publicado: (2020)

Neutrophils and secondary infections in COVID-19 induced acute respiratory distress syndrome
por: Holliday, Z.M., et al.
Publicado: (2021)

The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
por: Toma, Andrew, et al.
Publicado: (2021)

The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers
por: Chang, Kyung Hwa, et al.
Publicado: (2020)

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index
por: Terlizzi, Vito, et al.
Publicado: (2022)

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection
por: Okur, H.K., et al.
Publicado: (2020)

Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey
por: den Hollander, Bibiche, et al.
Publicado: (2022)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series
por: Weber, Andrew G., et al.
Publicado: (2020)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series
por: Weber, Andrew G., et al.
Publicado: (2020)

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022)

Intrapleural Tissue Plasminogen Activator and Dornase Alfa Administration for a Multiloculated Recurrent Malignant Pleural Effusion: A Case Report
por: Nikoomanesh, Kia, et al.
Publicado: (2022)

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
por: Desilles, J. P., et al.
Publicado: (2020)

A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study
por: Rozov, Tatiana, et al.
Publicado: (2013)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

USE OF ALTEPLASE AND DORNASE FOR LYSIS OF COVID-19-RELATED LOCULATED PLEURAL EFFUSION
por: STAIANO, PETER P, et al.
Publicado: (2022)

Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients
por: Pottecher, Julien, et al.
Publicado: (2020)

Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study
por: Jiang, Chuan, et al.
Publicado: (2020)

Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
por: Claudius, Casper, et al.
Publicado: (2015)

Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial
por: Livingston, Michael H., et al.
Publicado: (2017)

Congenital Zika Syndrome Is Associated With Interferon Alfa Receptor 1
por: Azamor, Tamiris, et al.
Publicado: (2021)

Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup
por: Xu, Huikang, et al.
Publicado: (2023)

NOTCH signaling in COVID-19: a central hub controlling genes, proteins, and cells that mediate SARS-CoV-2 entry, the inflammatory response, and lung regeneration
por: Baindara, Piyush, et al.
Publicado: (2022)

Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials
por: Sánchez Luna, Manuel, et al.
Publicado: (2020)

Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
por: Baindara, P., et al.
Publicado: (2021)

Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study
por: Ramanathan, R, et al.
Publicado: (2013)

Efficacy of Surfactant-TA, Calfactant and Poractant Alfa for Preterm Infants with Respiratory Distress Syndrome: A Retrospective Study
por: Jeon, Ga Won, et al.
Publicado: (2015)

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System
por: Urwyler, Pascal, et al.
Publicado: (2020)

Integrative proteomic profiling of lung tissues and blood in acute respiratory distress syndrome
por: Gong, Rui, et al.
Publicado: (2023)

Apoptotic cells for treatment of acute respiratory distress syndrome associated with COVID-19
por: van Heerden, Peter Vernon, et al.
Publicado: (2023)

Neonatal Respiratory Distress Secondary to Meconium Aspiration Syndrome
por: Olicker, Arielle L., et al.
Publicado: (2021)

Inhibition of the lectin pathway of complement activation reduces LPS-induced acute respiratory distress syndrome in mice
por: Ali, Youssif M., et al.
Publicado: (2023)

Whole-Blood Mitochondrial DNA Copies Are Associated With the Prognosis of Acute Respiratory Distress Syndrome After Sepsis
por: Hernández-Beeftink, Tamara, et al.
Publicado: (2021)

ALFA-PRF: a novel approach to detect murine perforin release from CTLs into the immune synapse
por: Rudd-Schmidt, Jesse A., et al.
Publicado: (2022)

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
por: Caracciolo, Massimo, et al.
Publicado: (2020)

The Role of Macrophages in the Pathogenesis of SARS-CoV-2-Associated Acute Respiratory Distress Syndrome
por: Kosyreva, Anna, et al.
Publicado: (2021)

Association of low ficolin-2 concentration in cord serum with respiratory distress syndrome in preterm newborns
por: Gajek, Gabriela, et al.
Publicado: (2023)

Hypoxemic Respiratory Failure from Acute Respiratory Distress Syndrome Secondary to Leptospirosis
por: Fernando, Shannon M., et al.
Publicado: (2017)

Alveolar Fluid Clearance in Pathologically Relevant Conditions: In Vitro and In Vivo Models of Acute Respiratory Distress Syndrome
por: Huppert, Laura A., et al.
Publicado: (2017)

The role of immunometabolism in macrophage polarization and its impact on acute lung injury/acute respiratory distress syndrome
por: Wang, Lian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ji3bllpofl9ijvqeke7o3afshr